Screener
Royalty Pharma RPRX Treasury Stock
Treasury Stock at other companies
Other financials
Where this comes from
Reported directly by Royalty Pharma in its filing.
Tagged under the XBRL concept us-gaap:TreasuryStockCommonValue.
The source filing: Royalty Pharma’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 9:02 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001802768-26-000015
| Line item | As of June 30, 2026 | As of December 31, 2025 |
|---|---|---|
| Class R redeemable shares, £1 par value; issued and outstanding: 2026–50 and 2025–50 | 63 | 63 |
| Deferred shares, $0.000001 par value; issued and outstanding: 2026–430,189 and 2025–411,475 | — | — |
| Additional paid-in capital | 4,376,266 | 4,123,088 |
| Retained earnings | 2,459,089 | 2,356,318 |
| Non-controlling interests | 2,952,975 | 3,238,039 |
| Treasury interests | (2,724) | (2,612) |
| Total shareholders’ equity | 9,785,714 | 9,714,939 |
| Total liabilities and shareholders’ equity | $19,819,771 | $19,620,780 |
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Royalty Pharma's treasury stock?
- Royalty Pharma (RPRX) reported treasury stock of $2.72M in Q2 2026.
- How has Royalty Pharma's treasury stock changed year-over-year?
- Royalty Pharma's treasury stock increased by 4.3% year-over-year, from $2.61M to $2.72M.
- What is the long-term trend for Royalty Pharma's treasury stock?
- Over 5 years (2020 to 2025), Royalty Pharma's treasury stock has grown at a 2.4% compound annual growth rate (CAGR), from $2.32M to $2.61M.
- What does treasury stock mean?
- Shares repurchased by the company and held in treasury, reducing equity. Recorded at cost and presented as a negative equity component.
Ask your AI about Royalty Pharma's treasury stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude